The products have been marketed by Pfizer and Wyeth's Fort Dodge operations. Elanco also will acquire a manufacturing facility in Sligo, Ireland, currently used in the production of animal vaccines. As part of the agreement, all Sligo employees will be offered positions with Elanco.
"The addition of this attractive portfolio of products and a world-class manufacturing facility is a natural fit for Elanco and positions us well for sustained growth," said Jeff Simmons, president, Elanco. "Through this acquisition, we will expand and diversify our European presence with new market-leading products, augment our growing portfolio of companion animal medicines and acquire new biologic and vaccine capabilities. We are excited about these new opportunities to improve animal health and protein production."
Pfizer was requested by the European Commission to divest these products as a result of Pfizer's acquisition last year of Wyeth, including Wyeth's Fort Dodge Animal Health business. Under terms of the agreement, Lilly will acquire European rights to a portfolio of marketed products, as well as a biological manufacturing facility in Sligo, Ireland. In return, Pfizer will receive an undisclosed upfront payment.
Both companies also have signed corresponding manufacturing supply agreements in order to ensure an uninterrupted supply of product to customers. Closing of the transaction is contingent upon clearance from European regulatory authorities and other customary closing conditions. No other terms of the transaction were disclosed.
